首页> Journal of medicinal chemistry> Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

导出 OA

翻译打印收藏纠错

第一作者： Justin A,Shapiro

第一单位： Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States.

作者： Justin A,Shapiro ^[1] ; Nathan J,Dupper ^[1] ; Breena,Fraga-Walton ^[1] ; Andrew T,Bockus ^[1] ; Siegfried S F,Leung ^[1] ; Kai,Yang ^[1] ; Chinmay,Bhatt ^[1] ; Megan K,DeMart ^[1] ; Miguel P,Baldomero ^[1] ; Luis,Hernandez ^[1] ; Gabriel,Fung ^[1] ; Sammy,Metobo ^[1] ; Steven,Xie ^[1] ; Bryan M,Lent ^[1] ; David C,Spellmeyer ^[1] ; Joshua,Luna ^[1] ; Dalena,Hoang ^[1] ; Manesh,Chand ^[1] ; Yuliana,Gritsenko ^[1] ; Catherine E,Gleason ^[1] ; Frances,Hamkins-Indik ^[1] ; Jie,Zheng ^[1] ; Ranya,Odeh ^[1] ; Meisam,Nosrati ^[1] ; Daphne,He ^[1] ; Ramesh,Bambal ^[1] ; Peadar,Cremin ^[1] ; Jinshu,Fang ^[1] ; Bernard,Levin ^[1] ; Evelyn W,Wang ^[1] ; Marie,Evangelista ^[1] ; David,Earp ^[1] ; Constantine,Kreatsoulas ^[1] ; Rajinder,Singh ^[1] ; Pablo D,Garcia ^[1] ; James B,Aggen ^[1]

作者单位： Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States. ^[1]